Schedule H2 in India: What the 2026 Expansion Means for Pharmaceutical Manufacturers

Schedule H2 in India: An Overview of the 2026 Expansion

Schedule H2 of the Drugs Rules, 1945 was introduced in November 2022 as a Barcode/QR Code Requirement for a fixed list of 300 brands. On 22 June 2026 it was widened to cover entire categories of medicines. For manufacturers of vaccines, antimicrobials, anticancer drugs and narcotic and psychotropic drugs, this is now a packaging, data and compliance planning issue with defined deadlines.

What Changed in Schedule H2 in 2026?

The Ministry of Health and Family Welfare notified the Drugs (Seventh Amendment) Rules, 2026 through G.S.R. 506(E) dated 22 June 2026, following public consultation on draft rules published on 16 October 2025. The government said it considered stakeholder objections and suggestions, and made the amendment after consulting the Drugs Technical Advisory Board. 

The existing 300-brand list was reorganised as “Table 1”, and a new “Table 2” extends the barcode/QR authentication requirement to entire therapeutic categories rather than named brands. The four categories are all vaccines, all antimicrobials, all narcotic and psychotropic drugs, and all anticancer drugs. 

Schedule H2 Compliance Timeline: 2027 and 2028 Deadlines

The rules come into force on 1 July 2027, except the antimicrobial’s entry (serial number 2 in Table 2), which comes into force on 1 July 2028. Manufacturers of vaccines, anticancer drugs and NDPS products therefore have until 1 July 2027 (about nine months from 30 September 2026), and antimicrobial manufacturers have until 1 July 2028 (about one year and nine months from the same date).

What Is Schedule H2 and What Does It Require?

Schedule H2 is an on-pack identification requirement. Lexplosion Solutions notes that the amendment extends existing on-pack identification rules and does not create a full end-to-end Track And Trace regime. The authentication requirement itself sits under Rule 96(6)-(7) of the Drugs Rules. Manufacturers must print or affix the barcode or QR code on the primary packaging label or, where space on the primary label is inadequate, on the secondary packaging. The amendment does not change the data fields already required; it widens the range of products to which they apply. 

The stated policy aims are better traceability, stronger supply-chain monitoring and less misuse of high-risk medicines. Government messaging framed the change around drug traceability and curbing misuse of high-risk medicines. The notification itself does not set out a detailed statement of reasons. As commentators such as Lexplosion Solutions note, for antimicrobials accurate identification and quality oversight are also relevant to antimicrobial resistance, since substandard or inadequately potent products can contribute to resistance. This is an interpretation rather than an official stated aim. 

What Schedule H2 Compliance Means for Pharmaceutical Manufacturers

Compliance is expected to involve early portfolio mapping, artwork redesign, printing-line upgrades and vendor contract revisions, and it affects manufacturers, loan-licensees and contract manufacturing organizations (CMOs).
In practice: 

• Portfolio mapping. Identify every SKU that falls into the four categories. The notification does not prescribe a route for resolving borderline cases, so our recommendation is to take ambiguous products up directly with the regulatory authority or State Licensing Authority rather than self-classify. 
• Packaging and artwork. Labels and cartons need space for a scannable code, and printing lines need equipment that can apply it reliably.
• Data readiness. The code has to carry accurate product and batch information, specifically: a unique product identification code, the proper and generic name, the brand name, the manufacturer’s name and address, the batch number, the dates of manufacture and expiry, the manufacturing licence number and, wherever applicable, details of excipients. This needs dependable data generation and record-keeping behind the packaging line.
• Third-party alignment. Loan licensees and CMOs are covered too, so contracts and quality agreements should assign responsibility for the coding requirement.
• Open scope questions. It is not stated whether veterinary formulations count towards “all antimicrobials” or “all vaccines”. Check this with the regulator before assuming either way.
• Lead time. The July 2027 and July 2028 dates give a transition period, but the work spans classification, packaging, technology, quality systems and third-party arrangements. Starting early avoids a late scramble for vendor and line capacity. 

How Pharmaceutical Manufacturers Can Prepare for Schedule H2 Compliance

1. Map your portfolio against Table 2 and resolve borderline classifications with the regulator.
2. Read the gazette notification (G.S.R. 506(E), 22 June 2026, Gazette of India Extraordinary) and the code specifications closely.
3. Audit packaging lines, artwork and data systems for readiness gaps.
4. Update supplier, CMO and loan-licence agreements.
5. Set an internal timeline that finishes before the effective dates.

Preparing for Schedule H2 Compliance in India

The 2026 amendment moves Schedule H2 from a brand list to category-wide coverage of some of the highest-risk medicines. The deadlines are fixed, and the practical work is packaging, data and contracts. Manufacturers who start mapping now will be in a better position when enforcement begins.

Jekson Vision can help you assess Schedule H2 readiness across your portfolio. 

Contact us at +91 6352 529 570 to discuss your compliance roadmap.